Status:
COMPLETED
Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus
Lead Sponsor:
Muhammad Aamir Latif
Conditions:
Status Epilepticus
Eligibility:
All Genders
1-16 years
Phase:
NA
Brief Summary
Brivaracetam is increasingly being studied in adult status epilepticus populations, evidence in pediatric patients remains sparse, with only limited case series and observational studies reporting fav...
Detailed Description
Given the urgent need for safe and effective alternatives in pediatric status epilepticus and the limited head-to-head data comparing intravenous brivaracetam with levetiracetam, especially in childre...
Eligibility Criteria
Inclusion
- Either gender
- Aged one month to 16 years
- Presenting with status epilepticus
Exclusion
- Previously received intravenous antiseizure medication for the current episode prior to presentation
- Known hypersensitivity to study drugs
- Hemodynamically unstable, requiring inotropic support before administration
Key Trial Info
Start Date :
January 16 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 16 2025
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT07163572
Start Date
January 16 2025
End Date
August 16 2025
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Children's Hospital and Institute of Child Health
Multan, Punjab Province, Pakistan, 66000